Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Operations: 2012-2024

Historic Cash from Operations for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $213.4 million.

  • Amphastar Pharmaceuticals' Cash from Operations fell 12.31% to $52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.3 million, marking a year-over-year decrease of 26.87%. This contributed to the annual value of $213.4 million for FY2024, which is 16.28% up from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Cash from Operations stood at $213.4 million, which was up 16.28% from $183.5 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Cash from Operations registered a high of $213.4 million during FY2024, and its lowest value of $57.3 million during FY2020.
  • Moreover, its 3-year median value for Cash from Operations was $183.5 million (2023), whereas its average is $162.0 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Cash from Operations declined by 8.99% in 2022 and then spiked by 105.76% in 2023.
  • Yearly analysis of 5 years shows Amphastar Pharmaceuticals' Cash from Operations stood at $57.3 million in 2020, then surged by 71.12% to $98.0 million in 2021, then decreased by 8.99% to $89.2 million in 2022, then spiked by 105.76% to $183.5 million in 2023, then increased by 16.28% to $213.4 million in 2024.